argenx vs Sanofi (ARGX.BR vs SAN.PA)

argenx (ARGX.BR) vs Sanofi (SAN.PA) in plain English: P/E, growth, margins, debt and dividend side by side, key differences and which fits each investor profile.

argenx (ARGX.BR) and Sanofi (SAN.PA) compete in healthcare and pharma. Here are argenx and Sanofi side by side with their real figures as of November 4, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy argenx or Sanofi.

argenx vs Sanofi: the figures

argenx and Sanofi figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026; N/A means that argenx or Sanofi figure is not available, and we never estimate it.

3 key differences between argenx and Sanofi

1. Growth: argenx grew sales +52.1% year on year in its latest quarter, against +15.7% for Sanofi.
2. Profitability: for every 100 of sales, argenx keeps 31.7 as net profit and Sanofi keeps 8.2.
3. Dividend: Sanofi pays a dividend yielding 5.09% and argenx pays none.

argenx or Sanofi: which fits your profile

• If you want growth: argenx is growing faster today, so it fits better with investors who put business growth first, usually accepting a higher P/E and a bumpier ride.
• If you want income (dividends): Sanofi pays the higher dividend relative to its price.
• If you prefer caution: argenx has less debt relative to its profit, which usually gives more room in a bad year.
• If price is what matters most to you: Sanofi trades on the lower P/E; check first whether that is an opportunity or a sign of a business that grows less.

Neither argenx nor Sanofi wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.

How argenx and Sanofi make money

argenx (ARGX.BR)

argenx is a biotech that earns its money from Vyvgart, its antibody-based treatment for autoimmune diseases such as myasthenia gravis and CIDP, sold in IV and under-the-skin forms. Nearly all sales come from this product, mostly in the US, followed by Japan and Europe, and it reinvests in research for new uses. Full argenx analysis.

Sanofi (SAN.PA)

Sanofi is a drugmaker focused on its Biopharma business: specialty medicines for immunology, rare diseases and neurology, led by Dupixent, its top-selling product, plus flu, pediatric and booster vaccines. It sells to hospitals, pharmacies and health systems, with the US and Europe as its main markets. Full Sanofi analysis.

Frequently asked questions: argenx vs Sanofi

Is argenx or Sanofi the better stock?

Choosing between argenx and Sanofi depends on what you are looking for. argenx is growing faster right now, and Sanofi trades on the lower P/E. Fintols does not tell you whether to buy argenx or Sanofi: it shows you the differences so you can decide.

Which pays a higher dividend, argenx or Sanofi?

As of November 4, 2026, Sanofi yields 5.09% and argenx pays none. Also check how much of their profit argenx and Sanofi pay out: if it is more than they earn, it cannot last.

Which is more expensive, argenx or Sanofi?

On P/E, argenx (32.8x) is more expensive than Sanofi (24.3x) as of November 4, 2026. A higher P/E can be justified if earnings grow faster, so compare it with each company's growth in the table.

Can I own both argenx and Sanofi?

Yes. Many people spread their money across several companies, such as argenx and Sanofi, or use index funds so they do not depend on just one. If you are starting out, decide how much you want to invest and for how long before buying argenx or Sanofi.

More comparisons with argenx or Sanofi

• argenx vs Bayer
• argenx vs Grifols
• argenx vs Laboratorios Rovi
• Bayer vs Sanofi

More companies like argenx and Sanofi: healthcare and pharma stocks. Educational content about argenx and Sanofi, not investment advice.